Overall, LINC00460 promoted the papillary thyroid cancer progression by regulating LINC00460/miR-485-5p/Raf1 axis, which might provide novel biomarkers for PTC treatment. The gene discussed is RAF1; the disease is thyroid gland papillary carcinoma.